1. Protein Tyrosine Kinase/RTK
  2. ALK

ALK

ALK (Anaplastic lymphoma kinase) is encoded by the ALK gene. ALK is a membrane associated tyrosine kinase receptor of the insulin receptor superfamily. The function of the full-length ALK receptor is poorly understood. It has a probable role in the central and peripheral nervous system development and maintenance. ALK is a dependence receptor, which may exert antagonist functions, proapoptotic or antiapoptotic, depending on the absence or presence of a ligand. Dependence receptors have a potential role in cancer and development. Ligands available for this demonstration were agonist anti-ALK antibodies. ALK is still an orphan receptor, given the high level of controversy about pleiotrophin and midkine.

ALK Related Products (24):

Cat. No. Product Name Effect Purity
  • HY-10432
    A 83-01 Inhibitor
    A 83-01 is a selective inhibitor of TGF-β type I receptor ALK5 kinase, type I activin/nodal receptor ALK4 and type I nodal receptor ALK7, with IC50 values of 12, 45 and 7.5 nM, respectively.
  • HY-50878
    Crizotinib Inhibitor 99.58%
    Crizotinib is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
  • HY-12678
    Entrectinib Inhibitor 98.42%
    Entrectinib is a potent and orally available Trk, ROS1, and ALK inhibitor; inhibits TrkA, TrkB, TrkC, ROS1 and ALK with IC50 values of 1, 3, 5, 12 and 7 nM, respectively.
  • HY-12215
    PF-06463922 Inhibitor 99.83%
    PF-06463922 is a novel, orally available, CNS-penetrant, ATP-competitive inhibitor of ALK/ROS1 with Ki of <0.02 nM, <0.07 nM, and 0.7 nM for ROS1, ALK (WT), and ALK (L1196M), respectively.
  • HY-12857
    Brigatinib Inhibitor 99.81%
    Brigatinib is a highly potent and selective ALK inhibitor, with IC50 of 0.6 nM.
  • HY-13011A
    CH5424802 Hydrochloride Inhibitor
    CH5424802 Hydrochloride is a potent, selective, and orally available ALK inhibitor with IC50 of 1.9 nM, the dissociation constant (KD) value for ALK in an ATP-competitive manner is 2.4 nM using a competition-bind assay.
  • HY-17603
    Belizatinib Inhibitor 99.20%
    Belizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC50 of 0.7 nM for wild-type recombinant ALK kinase.
  • HY-13011
    CH5424802 Inhibitor 98.43%
    CH5424802 is a potent, selective, and orally available ALK inhibitor with IC50 of 1.9 nM, the dissociation constant (KD) value for ALK in an ATP-competitive manner is 2.4 nM using a competition-binding assay.
  • HY-15656
    LDK378 Inhibitor 99.75%
    LDK378 is a potent and more specific ALK inhibitor with IC50 of 0.2 nM.
  • HY-10192
    NVP-TAE 684 Inhibitor 99.64%
    NVP-TAE684(TAE684) is a highly potent and selective small-molecule ALK inhibitor, which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC50 values between 2 and 10 nM.
  • HY-15656A
    LDK378 dihydrochloride Inhibitor 99.86%
    LDK378 2Hcl (Ceritinib) is potent inhibitor against ALK with IC50 of 0.2 nM, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively.
  • HY-50878A
    Crizotinib hydrochloride Inhibitor 99.86%
    Crizotinib hydrochloride is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
  • HY-15841
    CEP-37440 Inhibitor 99.87%
    CEP-37440 is a novel potent and selective Dual FAK/ALK inhibitor with IC50 s of 2.3 nM (FAK) and 120 nM(ALK cellular IC50 in 75% human plasma).
  • HY-13326
    ASP3026 Inhibitor 99.76%
    ASP3026 is a novel and selective inhibitor for ALK (anaplastic lymphoma kinase) with IC50 of 3.5 nM.
  • HY-15609
    AZD-3463 Inhibitor 99.57%
    AZD-3463 is an ALK/IGF1R inhibitor which overcomes multiple mechanisms of acquired resistance to crizotinib.
  • HY-13020
    GSK1838705A Inhibitor 98.99%
    GSK1838705A is a potent small-molecule IGF-IR, the insulin receptor and anaplastic lymphoma kinase (ALK) inhibitor with IC50 of 2.0, 1.6 and 0.5 nM, respectively.
  • HY-16590
    Ensartinib Inhibitor 98.02%
    Ensartinib is a potent inhibitor of ALK, which is used to treat non-small-cell lung cancer.
  • HY-13464
    ALK-IN-1 Inhibitor
    ALK-IN-1 is a potent and selective active inhibitor of anaplastic lymphoma kinase(ALK), Patent US20140066406 A1.
  • HY-15358
    ALK inhibitor 2 Inhibitor 99.43%
    ALK inhibitor 2 is a novel and selective inhibitor for the ALK kinase.
  • HY-15357
    ALK inhibitor 1 Inhibitor
    ALK inhibitor 1 is a novel and selective inhibitor for the ALK kinase.